Jeffrey Drew

iosBio Ltd. is a British UK-based biotechnology company that specializes in developing next-generation vaccines that can be administered orally. The company was founded by Jeffrey Drew and is based in Burgess Hill, UK. The company's proprietary orapro™ thermal stabilization technology enables the oral administration of thermally stable, non-replicating viral vectors that can be delivered sublingually via the gastrointestinal tract and other routes. iosBio is developing vaccines designed to stimulate mucosal, systemic, and T-cell immune responses, providing robust immunity to a number of infectious diseases, including COVID-19, Zika, and influenza.

iosBio Ltd. is a British UK-based biotechnology company that specializes in developing next-generation vaccines that can be administered orally. The company was founded by Jeffrey Drew and is based in Burgess Hill, UK. The company's proprietary orapro™ thermal stabilization technology enables the oral administration of thermally stable, non-replicating viral vectors that can be delivered sublingually via the gastrointestinal tract and other routes. iosBio is developing vaccines designed to stimulate mucosal, systemic, and T-cell immune responses, providing robust immunity to a number of infectious diseases, including COVID-19, Zika, and influenza.

iosBio Ltd. is a British UK-based biotechnology company that specializes in developing next-generation vaccines that can be administered orally. The company was founded by Jeffrey Drew and is based in Burgess Hill, UK. The company's proprietary orapro™ thermal stabilization technology enables the oral administration of thermally stable, non-replicating viral vectors that can be delivered sublingually via the gastrointestinal tract and other routes. iosBio is developing vaccines designed to stimulate mucosal, systemic, and T-cell immune responses, providing robust immunity to a number of infectious diseases, including COVID-19, Zika, and influenza.

iosBio Ltd. is a British UK-based biotechnology company that specializes in developing next-generation vaccines that can be administered orally. The company was founded by Jeffrey Drew and is based in Burgess Hill, UK. The company's proprietary orapro™ thermal stabilization technology enables the oral administration of thermally stable, non-replicating viral vectors that can be delivered sublingually via the gastrointestinal tract and other routes. iosBio is developing vaccines designed to stimulate mucosal, systemic, and T-cell immune responses, providing robust immunity to a number of infectious diseases, including COVID-19, Zika, and influenza.

iosBio Ltd. is a British UK-based biotechnology company that specializes in developing next-generation vaccines that can be administered orally. The company was founded by Jeffrey Drew and is based in Burgess Hill, UK. The company's proprietary orapro™ thermal stabilization technology enables the oral administration of thermally stable, non-replicating viral vectors that can be delivered sublingually via the gastrointestinal tract and other routes. iosBio is developing vaccines designed to stimulate mucosal, systemic, and T-cell immune responses, providing robust immunity to a number of infectious diseases, including COVID-19, Zika, and influenza.